Fig. 1From: Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort studyDescriptive statistics for complications recorded at any time during hospitalization, by patient group. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blockerBack to article page